Literature DB >> 10189642

Low-dose radiotherapy for lymphoid lesions of the orbit and ocular adnexa.

J S Kennerdell1, N E Flores, R J Hartsock.   

Abstract

PURPOSE: There is no agreement within the radiation oncology and ophthalmic communities regarding the treatment of lymphoid lesions of the orbit and ocular adnexa. The authors report their experience with the use of low-dose radiation therapy for malignant and benign lymphoid masses of the orbital region in a series of 54 patients treated between 1985 and 1993.
METHODS: All patients received 2 Gy per day for a total of 24 Gy, except when the lesion was extensive, in which case the therapy was 1.5 Gy per day for a total of 25.5 Gy. A diagnosis was established by incisional surgical biopsy in 26 patients and aspiration cytology in 28 patients. Those with a malignant or an indeterminate diagnosis were evaluated with a modified Ann Arbor staging system.
RESULTS: Low-dose radiation therapy produced a complete response in 100% of the orbital lymphoid lesions. This local control was maintained in 52 patients (96%) for the first year and in 51 patients (95%) for 5 or more years with a mean follow-up of 7 years. One patient died of causes unrelated to the malignant lymphoma after the first year of observation. The mean age of the 54 patients was 67 years, and the range was 37 to 90 years. The mean ages of presentation for each location were: orbit, 67 years; conjunctiva, 68 years; lacrimal gland, 66 years; and eyelids, 72 years. The female-to-male ratio was 1.25:1 (34 women and 20 men). In this series, 9 patients had benign processes, 38 patients had non-Hodgkin's lymphoma, and 7 patients had abnormalities of indeterminate cause. All histologic subtypes of non-Hodgkin's lymphoma involving the orbit responded equally well to therapy. Forty-five patients had clinically staged disease as follows: stage I, 21 patients; stage II, 4 patients; stage III, 2 patients; and stage IV, 18 patients. Benign disease, diagnosed in 9 patients, was not staged.
CONCLUSION: Low-dose radiation therapy proved effective in treating lymphoid lesions of the orbital area. No treatment-limiting complications occurred. The only early side effects were mild xerophthalmia and chemosis in 50% of patients, and the only chronic side effect was mild xerophthalmia in 33% of patients. Cataracts, corneal ulcerations, and retinal injury were not observed.

Entities:  

Mesh:

Year:  1999        PMID: 10189642     DOI: 10.1097/00002341-199903000-00012

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  14 in total

1.  [Diseases of the lacrimal gland].

Authors:  N Fichter; M Schittkowski; R F Guthoff
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

Review 2.  Retrospective study and review of ocular radiation side effects following external-beam Cobalt-60 radiation therapy in 37 dogs and 12 cats.

Authors:  Chantale L Pinard; Anthony J Mutsaers; Monique N Mayer; J Paul Woods
Journal:  Can Vet J       Date:  2012-12       Impact factor: 1.008

3.  Postconditioning hormesis put in perspective: an overview of experimental and clinical studies.

Authors:  F A C Wiegant; H A B Prins; R Van Wijk
Journal:  Dose Response       Date:  2010-08-12       Impact factor: 2.658

Review 4.  Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue.

Authors:  Dimitrios Kalogeropoulos; Alexandra Papoudou-Bai; Panagiotis Kanavaros; Chris Kalogeropoulos
Journal:  Clin Exp Med       Date:  2017-09-22       Impact factor: 3.984

5.  Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma.

Authors:  Chelsea C Pinnix; Bouthaina S Dabaja; Sarah A Milgrom; Grace L Smith; Zeinab Abou; Loretta Nastoupil; Jorge Romaguera; Francesco Turturro; Nathan Fowler; Luis Fayad; Jason Westin; Sattva Neelapu; Michelle A Fanale; Maria A Rodriguez; Frederick Hagemeister; Hun Ju Lee; Yasuhiro Oki; Michael Wang; Felipe Samaniego; Linda Chi; Bita Esmaeli
Journal:  Head Neck       Date:  2017-04-03       Impact factor: 3.147

6.  Ocular Complications After Radiation Therapy: An Observational Study.

Authors:  Raffaele Nuzzi; Marta Trossarello; Sara Bartoncini; Paola Marolo; Pierfrancesco Franco; Cristina Mantovani; Umberto Ricardi
Journal:  Clin Ophthalmol       Date:  2020-10-09

Review 7.  [Lymphoproliferative lesions of the ocular adnexa. Differential diagnostic guidelines].

Authors:  S E Coupland
Journal:  Ophthalmologe       Date:  2004-02       Impact factor: 1.059

8.  Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma.

Authors:  Sarah A Milgrom; Chan Y Cheah; Chelsea C Pinnix; Grace L Smith; Bouthaina S Dabaja; Patricia Horace; Patricia Chevez-Barrios; Nathan H Fowler; Dan S Gombos
Journal:  Leuk Lymphoma       Date:  2016-04-13

9.  Radiation Therapy Efficacy and Toxicity for Orbital and Ocular Adnexal Mucosa-Associated Lymphoid Tissue (OAMALT): A Single-Center, Retrospective Study of 32 Cases.

Authors:  Liping Xu; Xinyu Tang; Nan Jiang; Sheng Zhang; Yuandong Cao; Xinchen Sun
Journal:  Cancer Manag Res       Date:  2021-10-21       Impact factor: 3.989

10.  Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab.

Authors:  Aiyin Chen; Thomas N Hwang; Laura T Phan; Timothy J McCulley; Michael K Yoon
Journal:  Middle East Afr J Ophthalmol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.